Phase III DISCOVER-2a study of Tremfya shows efficacy and safety at two years in psoriatic arthritis.- Janssen Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the Phase III DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of Tremfya (guselkumab) previously demonstrated through 24 weeks (primary endpoint) and one year (week 52) in adults with active psoriatic arthritis (PsA) continued through two years (week 112). These findings show maintenance through two years of the benefits on improvement of joint symptoms and physical function. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference 2021, March 16-20. DISCOVER-1 is a randomised, double-blind, multicentre Phase III study evaluating the efficacy and safety of guselkumab administered by subcutaneous (SC) injection in participants with active PsA, including those previously treated with one or two biologic tumour necrosis factor inhibitors. DISCOVER-1 evaluated 381 participants and continued through approximately one year. DISCOVER-2 is a randomised, double-blind, multi-centre Phase III study evaluating the efficacy and safety of guselkumab administered by SC injection in patients with active PsA. DISCOVER-2 evaluated 739 participants and continued through approximately two years.